Date of publication February 19 2026 at 11 03 UTC. A completed clinical trial examines transcutaneous application of gaseous carbon dioxide to the lower part of the body for recurrent diabetic foot ulcers. The study is sponsored by University Medical Centre Ljubljana. The intervention uses a non invasive gas delivery method applied to the lower body as part of a device oriented approach to wound care in diabetes. The record is listed on ClinicalTrials.gov under identifier NCT07418073.
In this article we present a regulatory minded summary of what the completion means for devices that deliver gas through the skin. The information below is based on the trial record and public details from ClinicalTrials.gov. No efficacy data are described in the excerpt provided by the source text. Regulators and device developers may use this update to assess potential future directions for gas based therapies in diabetic foot care.
What is transcutaneous carbon dioxide therapy?
The intervention described in the record is a transcutaneous application of gaseous CO2 on the lower part of the body. This approach uses a non invasive gas delivery method with the aim of supporting wound management in people with diabetes who have recurrent ulcers on the feet. The therapy relies on gas exchange effects delivered through the skin rather than an orally administered drug or a systemic infusion. The documentation notes the intervention as a device oriented therapy rather than a medicinal product alone.
How is the delivery conceptualized?
The CO2 is applied via a device positioned on the lower body to enable a gas based treatment modality with potential local effects on tissue perfusion and healing processes according to the trial design described in the record.
What are the trial details?
The trial addresses the condition Ulcer Foot and uses transcutaneous gaseous CO2 as the intervention. The sponsor listed is University Medical Centre Ljubljana. The study status is Completed as indicated in the record. The ClinicalTrials.gov page is available at the provided link in the source text: ClinicalTrials.gov NCT07418073.
Intended use and performance claims are described in the record as part of the study design. The description focuses on the intervention and setting rather than presenting summarized outcomes in the excerpt given. Stakeholders should review the full registry entry for details on endpoints, population, and study design to assess how this trial aligns with regulatory expectations for device based therapies in diabetic foot care.
What are the regulatory implications?
The completion of a device oriented trial that involves transcutaneous CO2 delivery may influence regulatory considerations for potential products. Key questions for regulators and manufacturers include how the intended use is defined, what safety and performance claims are supported by the trial data, and what post market surveillance would be appropriate if a device were to advance based on this approach. The MDR style frame would require clear statements of intended purpose, performance characteristics, and safety assurances as presented by the sponsor or developer. This article discusses these aspects in the context of a completed trial and a public registry entry.
What safety considerations apply?
The source text does not provide a detailed safety profile. In a regulatory context this absence means stakeholders should seek complete safety data before advancing any product claim. If safety outcomes exist in the full trial report, those should be compared with established standards for non invasive gas delivery devices. Any future device would need to address exposure limits, skin integrity at the application site, and potential systemic effects of CO2 gas delivery to the lower body region. Regulators would expect a robust risk assessment and clearly documented mitigation measures.
What is next for stakeholders?
For clinicians, device developers and regulatory affairs teams the completed status signals potential interest in gas delivered therapies for difficult to treat foot ulcers in diabetes. Next steps would typically include a comprehensive public release of full study results, a review of risk benefit data, and planning for any further trials or regulatory filings. Stakeholders should monitor updates on the registry page and related regulatory communications to understand whether this approach progresses toward clinical use.
FAQ
- 1. When was the trial completed? The registry entry indicates the study status is Completed but does not specify a completion date in the provided excerpt.
- 2. Who conducted the trial? The sponsor listed is University Medical Centre Ljubljana, with the trial described in the source text as conducted under this entity.
- 3. What is the intervention? The intervention is transcutaneous application of gaseous CO2 on the lower part of the body.
- 4. Where can I find more information? The trial is listed on ClinicalTrials.gov, with the page referenced in the source text.
- 5. What should regulators look for next? Regulators will want full efficacy and safety data, details on device design and labeling, and clear intended use statements before consideration of any regulatory clearance or approval.
Conclusion
The completed trial of transcutaneous CO2 therapy for recurrent diabetic foot ulcers highlights a device oriented approach using a gas delivery method on the lower body. Regulators and manufacturers should seek full results to understand efficacy signals and safety outcomes. This update emphasizes the need for transparent data to support any future regulatory submissions for similar device based therapies.
Disclaimer
This article is intended for professional readers. It is not legal advice. Readers should consult regulatory counsel for obligation specific to their jurisdiction.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07418073?term=medical+device